Mohandas Sreelekshmy, Yadav Pragya D, Shete-Aich Anita, Abraham Priya, Vadrevu Krishna Mohan, Sapkal Gajanan, Mote Chandrashekhar, Nyayanit Dimpal, Gupta Nivedita, Srinivas Vellimedu Kannappa, Kadam Manoj, Kumar Abhimanyu, Majumdar Triparna, Jain Rajlaxmi, Deshpande Gururaj, Patil Savita, Sarkale Prasad, Patil Deepak, Ella Raches, Prasad Sai D, Sharma Sharda, Ella Krishna M, Panda Samiran, Bhargava Balram
Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India.
iScience. 2021 Feb 19;24(2):102054. doi: 10.1016/j.isci.2021.102054. Epub 2021 Jan 9.
The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.
获得一种安全有效的疫苗将是应对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)威胁的最终措施。在此,我们评估了灭活SARS-CoV-2候选疫苗BBV152A、BBV152B和BBV152C在叙利亚仓鼠中的免疫原性和保护效力。用候选疫苗进行的三种剂量接种方案诱导产生了高滴度的SARS-CoV-2特异性IgG和中和抗体。候选疫苗BBV152A和BBV152B显著产生了快速且强烈的免疫反应。在感染SARS-CoV-2后,接种疫苗的仓鼠肺部未出现任何组织病理学变化。通过病毒从下呼吸道的快速清除、上呼吸道病毒载量的降低、肺部无病变以及强烈的体液免疫反应,仓鼠的保护作用显而易见。这些发现证实了候选疫苗的免疫原性潜力以及对受SARS-CoV-2攻击的仓鼠的进一步保护作用。在这三种候选疫苗中,BBV152A表现出更好的反应。